More News! 6 Jun 2023 $5.5M funding for Oncopole to tackle cancer Oncopole, Fonds de recherche du Québec – Santé (FRQS) cancer division in Canada, has received major investments that boost its public-private partnership model dedicated to the fight against cancer. Oncopole will continue to pursue its mission thanks to a $3 million reinvestment from founding partner Merck Canada. Oncopole, FRQS cancer division, is the result of […] June 6, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jun 2023 Head and neck cancer data presented at ASCO 2023 Results from promising trials in the fight against head and neck cancer have been presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation, a provider of IT, network and AI technologies, announced new […] June 6, 2023 - 7 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Sponsored by Indivumed Therapeutics 6 Jun 2023 Optimizing early discovery by unraveling cancer complexity within precision therapeutics June 6, 2023 - 7 minutesmins - By Sudha Sundaram Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jun 2023 Shasqi using click chemistry to target cancer Shasqi, Inc., whose mission is to revolutionize cancer treatment with click chemistry, has entered into a research collaboration with Johnson & Johnson Enterprise Innovation Inc. Through the collaboration, Shasqi will apply its tumor-targeted Click Activated Protodrugs Against Cancer (CAPAC) platform to the development of new cancer therapies. Shasqi’s CAPAC platform relies on chemistry, not biology, […] June 6, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Podcast 2 Jun 2023Beyond Biotech podcast 48 BioInvent International AB, a Swedish biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, and Transgene, a biotech company that designs and develops virus-based immunotherapeutics against cancer, recently announced positive phase 1a data on the oncolytic virus BT-001 for the treatment of solid tumors. BioInvent currently has four […] June 2, 2023 Share WhatsApp Twitter Linkedin Email
News and Trends 2 Jun 2023 New approach improves cancer treatment and minimizes side effects Scientists at Tohoku University in Japan have discovered a new approach to improve the efficacy of immune checkpoint blockade (ICB) – a novel form of cancer treatment utilizing immune checkpoint inhibitors (ICIs) – while minimizing the associated side effects. They demonstrated that using ICIs to target tumor-positive lymph nodes generates a robust anti-tumor response against […] June 2, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Jun 2023 Anocca raises $36.6M for large-scale development of cancer cell therapies Anocca AB has raised SEK 400 million ($36.6 million) to further develop the discovery and manufacture of next generation cell therapies for cancer on an industrial scale. It will also allow Anocca to progress its first products into clinical trials. The financing brings together a group of existing and new investors, including Mellby Gård, AMF, […] June 2, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 30 May 2023 Pancreatic cancer microbiome discovery holds treatment hope iNtRON Biotechnology has announced the identification of prophage and (non-) ORF-jamphage from the microbiome frequently observed in long-term pancreatic cancer survivors. The company said the ‘significant identification’ was achieved as part of its ongoing PHAGERIARUS development project conducted by the new drug part of the company. The PHAGERIARUS development project is focused on acquiring bacteriophage-derived […] May 30, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 30 May 2023 Potential targets against natural killer/T-cell lymphoma found A team of researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) has discovered that a transcription factor, TOX2, was aberrantly increased in patients with natural killer/T-cell lymphoma (NKTL). The increased TOX2 level leads to the growth and spread of NKTL, as well as the overproduction of […] May 30, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 30 May 2023 Molecular Partners presenting positive solid tumor data Molecular Partners AG will present additional positive data from the ongoing phase 1 study of MP0317, a CD40 agonist designed to activate immune cells specifically within the tumor microenvironment by anchoring to fibroblast activation protein (FAP), at the 2023 ASCO (American Society of Clinical Oncology) annual meeting, June 2 to 6 in Chicago, U.S. The […] May 30, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Podcast 26 May 2023Beyond Biotech podcast 47 The companies Daiichi Sankyo and AstraZeneca have worked together for several years. This week’s podcast is sponsored by Daiichi Sankyo and AstraZeneca. On this week’s podcast, we have a conversation with Markus Kosch, the head of Oncology Europe and Canada for Daiichi Sankyo, and Greg Rossi, Senior Vice President, Oncology, Europe and Canada, from AstraZeneca, who are joining […] May 26, 2023 Share WhatsApp Twitter Linkedin Email
News and Trends 26 May 2023 Transgene and BioInvent report positive solid tumor results Transgene, a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, have announced positive phase Ia data on the oncolytic virus BT-001 for the treatment of solid tumors. Treatment with single agent […] May 26, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email